Makers of monkeypox drugs face a rash of orders
Defeating a worldwide outbreaks falls on two small drugmakers
Monkeypox isn’t covid-19. Since May the viral disease has infected 35,000 people in 92 countries, less than one-tenth as many as covid infects in a day. Though symptoms, including fever, headaches, muscle aches and a pus-filled rash, can be nasty, it seldom causes death. Critically, in contrast to covid, both a vaccine and a treatment predate the current epidemic. Their makers, two smallish drug companies, are struggling to keep up with demand.
This article appeared in the Business section of the print edition under the headline “A rash of orders”
From the September 17th 2022 edition
Discover stories from this section and more in the list of contents
Explore the editionMore from Business
What Elon Musk should learn from Larry Ellison
The founder of Oracle has demonstrated remarkable staying power
Football clubs are making more money than ever. Players not so much
For both teams and their top stars, it helps to have a brand
The allure of the company town
Lego, Corning and the survival of an old idea
From cribs to carriers, high-end baby products are in vogue
Demographic and technological changes are making infancy more expensive
No one gains from American tariffs on cars from Mexico and Canada
Donald Trump’s levy will hit his country’s carmakers hardest
DeepSeek poses a challenge to Beijing as much as to Silicon Valley
The story of Liang Wenfeng, the model-maker’s mysterious founder